Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic cardiomyopathy (HCM), at the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback